-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Capivasertib is a pan-AKT inhibitor.
preclinical data show that Capivasertib has therapeutic activity in metastatic desopathic prostate cancer (mCRPC) and works in synergy with dosi yew alcohol.
ProCAID study is a placebo-controlled phase II trial of mCRPC patients who were randomly assigned to oral Capivasertib (320 mg, 2/day, 4 days for 3 days, starting on the 2nd day of each course of treatment) or placebo after 10 courses of treatment.
endpoints are integrated progression-free survival (cPFS), including prostate-specific antigen progression events.
secondary endpoint is total survival (OS).
150 patients through cPFS and OS.
cPFS in the Capivasertib group and the placebo group was 7.03 months and 6.7 months, respectively (risk ratio of 0.92, 80% CI 0.73-1.16, p=0.32).
OS is 31.15 months and 20.27 months (HR 0.54, 95% CI 0.34-0.88, p-0.01), respectively.
regardless of the PI3K/AKT/PTEN signal path activation status, cPFS and OS results remain unchanged.
iii-IV and adverse reactions in both groups (62.2%).
most common adverse events associated with Capivasertib were diarrhea, fatigue, nausea and red rash.
results showed that for mCRPC patients, adding Capivasertib to chemotherapy did not further improve the patient's cPFS, regardless of the status of the PI3K/AKT/PTEN signal path.
the overall survival of each secondary endpoint, but further forward-looking validation is required.
。
